Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
Revision as of 05:11, 16 February 2009 by
Jacki Buros
(
talk
|
contribs
)
(
Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
moved to
News:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Redirect page
Jump to navigation
Jump to search
Redirect to:
News:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
Cookies help us deliver our services. By using our services, you agree to our use of cookies.
OK
Navigation menu
Personal tools
Log in
Request account
Namespaces
Home
Page
Discussion
English
Views
Read
View source
View history
Help
More
Tools
What links here
Related changes
Special pages
Printable version
Permanent link
Page information